“What we wanted to do was to substantiate any difference between BPH and alopecia with finasteride and also people who are concomitantly taking testosterone for hypogonadism,” says Kevin J. Campbell, MD, MS.
In this video, Kevin J. Campbell, MD, MS, discusses the background and findings of the study, “Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Campbell is an assistant professor in the department of urology at the University of Florida, Gainesville.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.